A study was undertaken of 44 patients who had developed fibrotic changes in the penis in the course of intracavernosal prostaglandin E1 (PGE1) injection therapy for erectile dysfunction. Of these patients, 75.0% (n ¼ 33) were followed up for more than 24 months, and 59.1% (n ¼ 26) for more than 36 months. Of the patients, 52.3% (n ¼ 23) had clinical improvement of the fibrotic changes without therapeutic intervention and despite most (91.3%) continuing intracavernosal PGE1 injection therapy. These included 25.0% (n ¼ 11) no longer having clinically detectable penile fibrosis (PF). The presence of penile curvature or pain did not significantly influence this outcome. The ages of men who showed improvement and the duration of their injection therapy were similar to those who did not improve. It would be prudent to defer therapeutic intervention for PF in the course of intracavernosal PGE1 injection therapy in anticipation of possible spontaneous improvement.
Introduction
There has been a change in the pharmacotherapy of erectile dysfunction (ED) since sildenafil (Viagra s ) became available as the first orally effective medication. ED is now often managed by primary-care or family physicians with sildenafil being offered as the drug of first choice. However, intracavernosal injection (ICI) therapy, using various vasoactive agents, particularly prostaglandin E1 (PGE1) or alprostadil (Caverject s ), still has an important role in the management of ED. 1 It is being used by patients who had previously received ICI therapy and found it efficacious and by new patients who may have contraindications or inadequate response to sildenafil.
Penile fibrosis (PF), a known complication of ICI therapy, refers to fibrotic changes in the subcutaneous tissues, the tunica albuginea or intracavernosal sinusoids of the penis. Its occurrence and prevalence have been well documented in the literature. [2] [3] [4] [5] [6] [7] [8] However, there have been few reports on the natural history of these fibrotic changes. We therefore studied the long-term outcome of PF that had developed in the course of intracavernosal PGE1 injection therapy.
Patients and method
We had previously studied 245 men receiving ICI therapy with PGE1 at the Keogh Institute for Medical Research, Australia. Fibrotic changes in the penis were found in 57 of these patients. The findings of that study, showing a prevalence of PF of 23.3%, were documented in a published report. 8 These patients continue to attend the Keogh Institute for review and when renewal of their prescriptions is required.
We conducted a follow-up study of this cohort of patients with PF. The penis was examined at each clinic attendance, and the persistence or otherwise, as well as any clinically detectable difference in the extent and severity, of the previously noted fibrotic changes were recorded. Specific inquiry was made regarding penile pain, curvature, deviation and deformity. Each patient was asked if he was still self-injecting with PGE1 and if there had been any change in the dose or frequency of the PGE1 used.
Results
Of the 57 men previously found to have PF, 44 (77.2%) were available for follow-up; 11 had ceased attending the Keogh Institute for further treatment. One patient switched over to papaverine in preference to PGE1 because of post-injection pain, and the records of one patient were mislaid or lost.
The mean follow-up period was 43.8 months (range 4-71). Of the patients, 75.0% (33/44) were followed up for more than 24 months, and 59.1% (26/44) for more than 36 months ( Table 1) .
The overall results are as shown in Table 2 . In 23 (52.3%) of the 44 men, there was clinical evidence of improvement in the fibrosis, with 11 (25.0%) no longer having clinically detectable PF at follow-up.
Other findings according to the state of PF are as follows and are summarized in Tables 3 and 4 .
(a) Patients without clinically significant change in PF There were 21 patients in this group. At the time PF was initially detected, the mean age of these patients was 63.4 y (range 40.4-74.0), and the mean duration of intracavernosal PGE1 injection therapy was 28.0 months (range 2-85). No clinically significant change in PF was detected after a mean followup period of 35.8 months (range 6-71). At the end of the follow-up period, the mean total period of ICI therapy was 64.6 months (range 9-136).
Penile curvature or deviation was present in 8 (38.1%) and penile pain in five patients (23.8%) when PF was initially detected. In four patients, the curvature persisted without change while it disappeared in two patients. Pain persisted in two of the patients and improved in one patient. In the course of the follow-up, seven In all, 13 patients (61.9%) continued to use intracavernosal PGE1 for ED at about the same frequency as before. The mean dose of PGE1 used was 16.0 mcg (range 5-35) when PF was first noted and 26.8 mcg (range 3-50) at the end of the follow-up period. Two patients were able to use the same dose, while an increased dose was required in nine patients and two patients reduced their dose of PGE1 used. The reasons for discontinuing ICI therapy by eight patients are shown in Table 4 . At the time PF was first detected, the mean age of these 23 patients was 64.5 y (range 49.9-79.4) and the mean duration of ICI therapy was 33.7 months (range 5-80). Improvement was noted in 18 of the 23 patients after a mean followup period of 28.1 months (range 13-59). At the time improvement was noted, the mean age of these 18 patients was 66.5 y (range 53.6-82.1), and they had used ICI therapy for a mean total duration of 64.2 months (range 28-106).
In five of the 23 patients, it was difficult to know when improvement might have occurred as it was observed after a long period of absence from followup.
Penile curvature or deviation was present in five patients (21.7%) and penile pain in seven patients (30.4%). Curvature remained unchanged in two, improved in one and disappeared in two patients. Pain persisted in three and disappeared in the remaining four patients. In the course of the follow-up, one patient complained of penile pain for the first time.
A total of 21 patients (91.3%) continued with intracavernosal PGE1 injection therapy. The mean dose of PGE1 used was 10.1 mcg (range 1-25) when PF was first noted and 11.5 mcg (range 1-40) when improvement was noted. In the course of the follow-up, the dose of PGE1 remained unchanged in nine patients, while nine patients had to use an increased dose and three patients were able to use a smaller dose. Two patients discontinued ICI and used sildenatil in preference. 
Patients no longer with clinically detectable PF
The subset of 11 patients who no longer had clinically detectable PF was studied. When PF was initially detected, the mean age of these 11 patients was 67.8 y (range 49.9-79.4) and the duration of ICI therapy was 31.0 months (range 5-75). PF was no longer clinically detectable in eight of the 11 patients after a mean period of followup of 28.0 months (range 19-34). At the time PF was no longer clinically detectable, the mean age of these eight patients was 70.6 y (range 54.3-82.1), and they had used ICI therapy for a mean total duration of 61.3 months (range 28-106).
In three of the 11 patients, it was difficult to know when PF might have resolved as they had been absent from follow-up for a long period when finaIly seen.
Penile curvature or deviation was present in two patients (18.3%), and penile pain in three patients (27.3%). Curvature improved in one patient and disappeared in the other patient. Pain remained unchanged in one patient and disappeared in the remaining two patients.
All the 11 patients continued with ICI therapy using PGE1. The mean dose of PGE1 was 12.7 mcg (range 3-25) when PF was first noted and 15.2 mcg (range 5-40) when PF was no longer clinically detectable. Five patients used the same dose of PGE1, while five had to increase the dose and one used a smaller dose.
Discussion
We found that 23 (52.3%) of the 44 patients had clinical improvement of the fibrotic changes in their penis without any specific therapeutic intervention, including 25% no longer having clinically detectable PF. Of these 23 patients, 21 had continued ICI therapy.
In a previously reported study involving 683 men receiving intracavernosal PGE1 injections over a period of 18 months, 51 men were found to have PF. Of these men 15 continued with the injection therapy and in nine (60%) of them, the fibrosis completely resolved. 9 In another study, fibrotic changes in the penis were found to disappear in nine of 18 patients (50%) within 3 y. 10 With further follow-up of the patients in our study, it is possible that a similar rate of spontaneous resolution of PF may eventuate.
It is unclear what might have favoured improvement and disappearance of the fibrotic changes. At the initial detection of the fibrotic changes, there was no difference in the mean age and the duration of ICI therapy between the group that subsequently showed improvement and the group that did not. From our previous study, age appeared to be significantly associated with the occurrence of fibrotic changes and showed a linear relationship with the presence of PF. However, age did not seem to be an impediment to spontaneous resolution as the mean age of patients was 70.6 y when PF was no longer clinically detectable.
The presence of penile curvature or penile pain associated with PF did not significantly influence improvement or resolution of the fibrotic changes.
The mean dose of PGE1 used by those without clinically significant change in PF was 16.0 mcg initially, increasing to 26.8 mcg in the course of the follow-up, compared to 10.1 and 11.5 mcg, respectively, used by those with improvement. Proportionately, a greater number of patients in the former group had to significantly increase the dose of PGE1 used. In our previous study, we found that PF was significantly correlated with the total amount of PGE1 used over the whole treatment period. 8 It is conjectural whether persistent fibrotic changes might have aggravated ED necessitating an increased dose of PGE1 or whether increased doses of PGE1 might have contributed to the persistence of PF.
Various mechanisms had been suggested for the occurrence of PF in intracavernosal PGE1 injection therapy. 7, 8 These include: (a) tunical tear associated with age-related reduction of elastic fibres, (b) ischaemic injury to the tunica albuginea and (c) vasculitis in the subtunical tissues. While each of these suggestions appears plausible as the basis of fibrogenesis, the mystique of spontaneous improvement and resolution of PF remains when this occurs despite the continuation of ICI therapy.
Conclusion
A follow-up of 44 patients who developed PF in the course of intracavernosal PGE1 injection therapy for ED showed that a significant number had clinically detectable improvement and resolution of the fibrotic changes without therapeutic intervention in spite of continuing ICI therapy with PGE1. The finding is relevant when counselling patients prior to their participation in an ICI therapy programme and on detecting fibrotic changes in their penis in the course of ICI therapy. It would be prudent to defer therapeutic intervention for PF in anticipation of possible spontaneous improvement and resolution.
